Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Pembrolizumab

Immune mediated enteritis and pneumonitis

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Moreira I, et al. IMMUNE MEDIATED PNEUMONITIS AND ENTERITIS RELATED TO IMMUNE CHECKPOINT INHIBITOR THERAPY FOR LUNG CANCER. European Journal of Case Reports in Internal Medicine 8 (Suppl. 1): 288 abstr. PV725 / #1264, Feb 2024. Available from: URL: https://dx.doi.org/10.12890/2021_V8Sup1 [abstract] Moreira I, et al. IMMUNE MEDIATED PNEUMONITIS AND ENTERITIS RELATED TO IMMUNE CHECKPOINT INHIBITOR THERAPY FOR LUNG CANCER. European Journal of Case Reports in Internal Medicine 8 (Suppl. 1): 288 abstr. PV725 / #1264, Feb 2024. Available from: URL: https://​dx.​doi.​org/​10.​12890/​2021_​V8Sup1 [abstract]
Metadaten
Titel
Pembrolizumab
Immune mediated enteritis and pneumonitis
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54243-6

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Tocilizumab

Case report

Daratumumab

Case report

Hydralazine

Case report

Clozapine